



3/2026/Z/FAIND2.0

Att. no. 2

In connection with the implementation of project no. 2022/ABM/05/00005 under the name **"FGF1 analog: a novel therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases"** CELON PHARMA SA, based in Kielpin, invites tenders for the supply of:

Device for defrosting cell banks designed for operation in GMP conditions in cleanliness class C.

The device in question must be brand new, manufactured no earlier than 2025, unused in any laboratory and not exhibited at conferences or trade fairs, and must meet the technical and functional requirements specified in the description of the subject of the contract, including transport, installation, validation, commissioning and staff training. The following description of the subject of the contract presents the minimum requirements for the device being procured. Contractors participating in the procedure should propose a device with parameters equal to or exceeding those indicated below.

DESCRIPTION OF THE SUBJECT OF THE ORDER

Minimum required parameters	Parameters of the item offered (to be completed by the Tenderer)
Device for throwing cell banks – 1 unit	
The device has a tube holder compatible with most popular tube models (vials) from manufacturers such as Corning and Brand.	
Compatible with vials with external and internal threads	
The device must provide a repeatable, controlled thawing temperature profile, minimising thermal stress on cells.	
Temperature sensor calibration certificate	
Range of defrosted medium volume: 1.0 ml – 2.0 ml	
Maximum bank defrosting time: 3 minutes	
Defrosting time and temperature monitored and recorded in real time	
Operating range of defrosting temperatures that does not adversely affect the defrosted cell banks	

Celon Pharma S.A.

Biuro główne: Ogrodowa 2A, Kielpin
05-092 Łomianki, Polska
telefon: +48 22 751 59 33
fax: +48 22 751 44 58
e-mail: info@celonpharma.com

Organ rejestrujący: Sąd Rejonowy dla Miasta Stołecznego Warszawy w Warszawie
XIV Wydział Gospodarczy Krajowego Rejestru Sądowego
Prezes Zarządu: Maciej Wieczorek
KRS; 0000437778
Kapitał zakładowy: 5 103 500 PLN
NIP: 118 – 16 – 42 – 061
www.celonpharma.com



Device dimensions not exceeding 12 cm x 15 cm	
The device has the following certificates: IEC61326, IEC61010, RoHS, WEEE	
The device draws power from an AC socket: 230 V, 50 Hz.	
Device powered by 12 V DC	
The device features an automatic cell bank defrosting programme and has a pre-installed defrosting algorithm.	
The defrost programme can be edited and tailored to the user's needs.	
The device is free from water defrosting systems.	
The device can defrost cell banks stored in liquid nitrogen vapour.	
The device enables the thawing of cell banks (vials) at a temperature of 37°C.	
The device informs the user that the defrosting process is complete by means of light and sound signals.	
Device adapted for thawing banks using cryoprotectants such as 10% DMSO or 20% FBS or 70% DMEM	
The device has IQ/OQ qualification.	
Possibility of validating the defrosting process (reproducibility of parameters)	
Smooth surfaces, resistant to common alcohol-based disinfectants and cleaning agents	
Surface made of non-corrosive material that does not generate solid particles into the environment	
Instruction manual in Polish and/or English	
Display (indicator lights) showing the status of the appliance and the defrosting process	
Device adapted for operation under GMP conditions	

Celon Pharma S.A.

Biuro główne: Ogrodowa 2A, Kielcin
05-092 Łomianki, Polska
telefon: +48 22 751 59 33
fax: +48 22 751 44 58
e-mail: info@celonpharma.com

Organ rejestrujący: Sąd Rejonowy dla Miasta Stołecznego Warszawy w Warszawie
XIV Wydział Gospodarczy Krajowego Rejestru Sądowego
Prezes Zarządu: Maciej Wieczorek
KRS: 0000437778
Kapitał zakładowy: 5 103 500 PLN
NIP: 118 – 16 – 42 – 061
www.celonpharma.com



Additional requirements		
Warranty	The minimum warranty period is 24 months .	
Staff training	Installation and training on the day and at the place of installation for an unlimited number of persons in the operation of the device and necessary maintenance operations.	
Service	The contractor provides manufacturer-authorised warranty and post-warranty service within the territory of the Republic of Poland..	YES/NO
Fault reporting	The contractor provides the possibility of reporting camera malfunctions 24 hours a day, 365 days a year.	YES/NO
Contractor's response	Response time to a fault report:	Within 24 hours of notification/more than 24 hours after notification
Fault rectification	The contractor undertakes to rectify the fault within the specified time:	Up to 2 working days (48 hours) and, in the case of parts imported from abroad, up to 14 working days/more than 2 working days (48 hours) and, in the case of parts imported from abroad, more than 14 working days.

.....
(signature of the Contractor or a person authorised on behalf of the Contractor)

Celon Pharma S.A.

Biuro główne: Ogrodowa 2A, Kielpin
05-092 Łomianki, Polska
telefon: +48 22 751 59 33
fax: +48 22 751 44 58
e-mail: info@celonpharma.com

Organ rejestrujący: Sąd Rejonowy dla Miasta Stołecznego Warszawy w Warszawie
XIV Wydział Gospodarczy Krajowego Rejestru Sądowego
Prezes Zarządu: Maciej Wieczorek
KRS; 0000437778
Kapitał zakładowy: 5 103 500 PLN
NIP: 118 – 16 – 42 – 061
www.celonpharma.com